دواعي استعمال بروليا 60مجم سرنجة معبأة

Denosumab 60 mg prefilled syringe (Prolia, Amgen; distributed in Egypt by Multipharma), a RANKL inhibitor monoclonal antibody given subcutaneously every 6 months for osteoporosis.

• Postmenopausal women with osteoporosis at high risk for fractureالفئة: Postmenopausal womenDailyMed (NLM)
• To increase bone mass in men with osteoporosis at high risk for fractureالفئة: MenDailyMed (NLM)
• Glucocorticoid-induced osteoporosis in men and women at high risk for fractureالفئة: AdultsDailyMed (NLM)
• Bone loss in men on androgen deprivation therapy for nonmetastatic prostate cancer and women on adjuvant aromatase inhibitor therapy for breast cancerالفئة: AdultsDailyMed (NLM)

• Hypocalcemia (correct before treatment), pregnancy, and history of systemic hypersensitivity to any component.نشرة دولية لنفس المنتج · DailyMed (NLM)

• Boxed warning: severe hypocalcemia, including fatal cases, in patients with advanced chronic kidney disease (eGFR < 30 mL/min/1.73 m2) including dialysis.نشرة دولية لنفس المنتج · DailyMed (NLM)
• Do not use with other denosumab products; hypersensitivity/anaphylaxis; osteonecrosis of the jaw; atypical femoral fractures; multiple vertebral fractures after discontinuation; serious infections; dermatologic reactions; suppression of bone turnover.نشرة دولية لنفس المنتج · DailyMed (NLM)

• Calcimimetic drugsConcomitant use may worsen hypocalcemia risk.DailyMed (NLM)
• Other denosumab productsShould not be given concomitantly (same active ingredient).DailyMed (NLM)

• Contraindicated in pregnancy; may cause fetal harm. Pregnancy testing is recommended before initiating treatment in women of reproductive potential.نشرة دولية لنفس المنتج · DailyMed (NLM)

• Monitor serum calcium; ensure adequate calcium and vitamin D supplementation.نشرة دولية لنفس المنتج · DailyMed (NLM)

• Binds RANKL, preventing activation of RANK on osteoclasts and their precursors, reducing bone resorption.